These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 18505909)

  • 1. Extremely long survival in six patients despite recurrent and metastatic adrenal carcinoma.
    Hermsen IG; Gelderblom H; Kievit J; Romijn JA; Haak HR
    Eur J Endocrinol; 2008 Jun; 158(6):911-9. PubMed ID: 18505909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapy of the adrenocortical carcinoma with Lysodren (o,p'-DDD). Therapeutic management by monitoring o,p'-DDD blood levels].
    Heilmann P; Wagner P; Nawroth PP; Ziegler R
    Med Klin (Munich); 2001 Jul; 96(7):371-7. PubMed ID: 11494911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there a role for low doses of mitotane (o,p'-DDD) as adjuvant therapy in adrenocortical carcinoma?
    Dickstein G; Shechner C; Arad E; Best LA; Nativ O
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3100-3. PubMed ID: 9745410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adrenocortical carcinoma.
    Decker RA; Kuehner ME
    Am Surg; 1991 Aug; 57(8):502-13. PubMed ID: 1928992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The surgical management of adrenal cortical carcinoma.
    Linos DA; Vassilopoulos PP; Papadimitriou J; Tountas K
    Int Surg; 1986; 71(2):104-6. PubMed ID: 3733353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete remission of metastasized adrenocortical carcinoma under o,p'-DDD.
    Kornely E; Schlaghecke R
    Exp Clin Endocrinol; 1994; 102(1):50-3. PubMed ID: 8005209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Surgical strategy in the treatment of adrenal cortex cancer. Expanded and repeated interventions].
    Borrelli D; Bergamini C; Borrelli A; Reddavide S; Lassig R; Valeri A
    Ann Ital Chir; 2003; 74(3):311-7. PubMed ID: 14677288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma.
    Fassnacht M; Hahner S; Polat B; Koschker AC; Kenn W; Flentje M; Allolio B
    J Clin Endocrinol Metab; 2006 Nov; 91(11):4501-4. PubMed ID: 16895957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorodesoxyglucose uptake in the remaining adrenal glands during the follow-up of patients with adrenocortical carcinoma: do not consider it as malignancy.
    Leboulleux S; Deandreis D; Escourrou C; Al Ghuzlan A; Bidault F; Aupérin A; Travagli JP; Lumbroso J; Schlumberger M; Baudin E
    Eur J Endocrinol; 2011 Jan; 164(1):89-94. PubMed ID: 20921280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitotane treatment for adrenocortical carcinoma: an overview.
    De Francia S; Ardito A; Daffara F; Zaggia B; Germano A; Berruti A; Di Carlo F
    Minerva Endocrinol; 2012 Mar; 37(1):9-23. PubMed ID: 22382612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adrenocortical tumors in children.
    Ciftci AO; Senocak ME; Tanyel FC; Büyükpamukçu N
    J Pediatr Surg; 2001 Apr; 36(4):549-54. PubMed ID: 11283875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cortisol as a possible marker of metastatic adrenocortical carcinoma: a case report with 3-year follow-up.
    Schwarte S; Brabant EG; Bastian L; Bruns F
    Anticancer Res; 2007; 27(4A):1917-20. PubMed ID: 17649795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma.
    Gonzalez RJ; Tamm EP; Ng C; Phan AT; Vassilopoulou-Sellin R; Perrier ND; Evans DB; Lee JE
    Surgery; 2007 Dec; 142(6):867-75; discussion 867-75. PubMed ID: 18063070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines.
    Cerquetti L; Bucci B; Marchese R; Misiti S; De Paula U; Miceli R; Muleti A; Amendola D; Piergrossi P; Brunetti E; Toscano V; Stigliano A
    Endocr Relat Cancer; 2008 Jun; 15(2):623-34. PubMed ID: 18509009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Score Predicting Long-Term Survival after Repeat Resection for Recurrent Adrenocortical Carcinoma.
    Tran TB; Maithel SK; Pawlik TM; Wang TS; Hatzaras I; Phay JE; Fields RC; Weber SM; Sicklick JK; Yopp AC; Duh QY; Solorzano CC; Votanopoulos KI; Poultsides GA
    J Am Coll Surg; 2016 Dec; 223(6):794-803. PubMed ID: 27618748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement.
    Hogan TF; Citrin DL; Johnson BM; Nakamura S; Davis TE; Borden EC
    Cancer; 1978 Nov; 42(5):2177-81. PubMed ID: 719602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adrenocortical carcinoma. Our experience.
    Favia G; Lumachi F; Carraro P; D'Amico DF
    Minerva Endocrinol; 1995 Mar; 20(1):95-9. PubMed ID: 7651289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitotane effects in a H295R xenograft model of adjuvant treatment of adrenocortical cancer.
    Lindhe O; Skogseid B
    Horm Metab Res; 2010 Sep; 42(10):725-30. PubMed ID: 20665429
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A case of recurrent adrenocortical carcinoma, with observations on long-term o,p'-DDD therapy and complications.
    van Aalderen W; van Seters AP; Backer ET; Chang PC; van Krieken JH; Moolenaar AJ
    Neth J Med; 1992 Oct; 41(3-4):161-70. PubMed ID: 1470288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma.
    Kroiss M; Plonné D; Kendl S; Schirmer D; Ronchi CL; Schirbel A; Zink M; Lapa C; Klinker H; Fassnacht M; Heinz W; Sbiera S
    Eur J Endocrinol; 2016 Mar; 174(3):343-53. PubMed ID: 26671975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.